{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:00:19Z","timestamp":1785150019434,"version":"3.55.0"},"reference-count":156,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background\/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD), a leading cause of chronic liver disease, encompasses a continuum from steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. This review aimed to synthesize current evidence on how metabolomic, lipidomic, and spatial multi-omic approaches illuminate MASLD pathogenesis and support precision hepatology. Methods: A structured narrative review was conducted through searches of PubMed, Scopus, and Web of Science, complemented by manual screening of key references. Studies were prioritized when they addressed MASLD biology, metabolic rewiring, lipid remodeling, mitochondrial dysfunction, inflammatory and fibrogenic pathways, gut\u2013liver\u2013adipose crosstalk, biomarker development, or therapeutic monitoring. Results: The reviewed evidence identifies MASLD as a systemic metabolic disorder shaped by excess lipid flux, enhanced de novo lipogenesis, impaired mitochondrial adaptation, oxidative and endoplasmic reticulum stress, sterile inflammation, and hepatic stellate-cell activation. Recurrent metabolomic signatures include altered amino acid, fatty acids, bile acid, and microbial co-metabolite pathways. Lipidomic studies consistently implicate depletion of protective polyunsaturated fatty acids, lysophosphatidylcholines, and phosphatidylcholines, in association with accumulation of diacylglycerols and ceramides, in the transition from steatosis to MASH and fibrosis. Emerging spatial and multi-omic analyses further resolve cell-specific metabolic niches involving hepatocytes, macrophages, endothelial cells, and stellate cells. Conclusions: Metabolomics provides a mechanistic and translational bridge between molecular injury, histological progression, and non-invasive risk stratification in MASLD. Future progress requires standardized analytical workflows, longitudinal validation, causal pathway interrogation, and integration with imaging, genetics, microbiome profiling, and treatment-response phenotyping. Clinical implementation will require standardized platforms, transparent metabolite identification, external validation across diverse populations, cost-effectiveness analyses, and regulatory-grade evidence of clinical utility.<\/jats:p>","DOI":"10.3390\/metabo16080529","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:47:41Z","timestamp":1785145661000},"page":"529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"first","affiliation":[{"name":"Independent Researcher, 41100 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0931","authenticated-orcid":false,"given":"Ralf","family":"Weiskirchen","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Leoni, S., Alswat, K.A., and Fouad, Y. (2020). History of Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165888"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cld.2026.01.001","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease: Global Epidemiology, Patient-Reported Outcomes, and Economic Impact","volume":"30","author":"Paik","year":"2026","journal-title":"Clin. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.jhep.2024.03.039","article-title":"Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both","volume":"81","author":"Zhou","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100586","DOI":"10.37349\/edd.2025.100586","article-title":"MASLD vs. MAFLD. A narrative review","volume":"4","author":"Lonardo","year":"2025","journal-title":"Explor. Dig. Dis."},{"key":"ref_5","first-page":"e76","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Vessby","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1013713905833","article-title":"Metabolomics\u2014The link between genotypes and phenotypes","volume":"48","author":"Fiehn","year":"2002","journal-title":"Plant Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.060368","article-title":"Metabolomic Profiling for the Identification of Novel Biomarkers and Mechanisms Related to Common Cardiovascular Diseases","volume":"126","author":"Shah","year":"2012","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Al-Sulaiti, H., Almaliti, J., Naman, C.B., Al Thani, A.A., and Yassine, H.M. (2023). Metabolomics Approaches for the Diagnosis, Treatment, and Better Disease Management of Viral Infections. Metabolites, 13.","DOI":"10.3390\/metabo13080948"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1039\/D3NP00050H","article-title":"Connecting metabolome and phenotype: Recent advances in functional metabolomics tools for the identification of bioactive natural products","volume":"41","author":"Vitale","year":"2024","journal-title":"Nat. Prod. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Fang, L., Kim, I.S., Martin, B.R., Sherlock, L., Min, S., Kim, Y.K., and Mok, K.H. (2026). Metabolomics and Human Health: Progress, Insights, Challenges and the Concept of a Healthy Metabolome. Biomolecules, 16.","DOI":"10.3390\/biom16050683"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s43856-026-01383-2","article-title":"Diagnosing and defining MASLD in people living with chronic hepatitis B","volume":"6","author":"Martyn","year":"2026","journal-title":"Commun. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101853","DOI":"10.1016\/j.xcrm.2024.101853","article-title":"Metabolomics at the cutting edge of risk prediction of MASLD","volume":"5","author":"Tan","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MCG.0000000000002079","article-title":"Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals with Type 2 Diabetes Mellitus","volume":"59","author":"Ahmadizar","year":"2025","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Naja, K., Anwardeen, N., and Elrayess, M.A. (2025). Metabolomic Signatures of MASLD Identified by the Fatty Liver Index Reveal Gamma-Glutamyl Cycle Disruption and Lipid Remodeling. Metabolites, 15.","DOI":"10.3390\/metabo15110687"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102522","DOI":"10.1016\/j.xcrm.2025.102522","article-title":"Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD","volume":"7","author":"Huang","year":"2026","journal-title":"Cell Rep. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sprinkles, J.K., Qin, Q., Steward, C., Howard, A.G., Lulla, A., Hullings, A.G., Carr, J.J., Shaikh, S.R., Avery, C.L., and North, K.E. (2026). Plasma lipidomics, choline metabolites, and metabolic-associated steatotic liver disease (MASLD): A Coronary Artery Risk Development in Young Adults (CARDIA) study. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0341462"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Beyo\u011flu, D., Popov, Y.V., and Idle, J.R. (2024). Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312809"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.dld.2024.05.015","article-title":"Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients","volume":"56","author":"Babu","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tan, J., Taitz, J., Nanan, R., Grau, G., and Macia, L. (2023). Dysbiotic Gut Microbiota-Derived Metabolites and Their Role in Non-Communicable Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015256"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Maimaitiyiming, M., Maihemuti, S., Aierken, T., Abulimiti, G., Aibaidula, T., Guan, Y., Simayi, A., Aimaiti, M., Wang, X., and Abuduaini, A. (2025). Multi-omics analysis reveals gut microbial and metabolic signatures in metabolic dysfunction-associated steatotic liver disease. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1666110"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119054","DOI":"10.1016\/j.atherosclerosis.2024.119054","article-title":"Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics","volume":"400","author":"Flam","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/s41588-025-02407-8","article-title":"Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Li","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s42003-025-09122-4","article-title":"Multi-modal label-free imaging of cellular metabolism and oxidative stress in 3D brain tissue models","volume":"8","author":"Zhang","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11033-026-11447-0","article-title":"MASLD biomarker discovery: Evaluating lipidomics techniques across disease progression","volume":"53","author":"Hassanein","year":"2026","journal-title":"Mol. Biol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Thing, M., Werge, M.P., Kimer, N., Hetland, L.E., Rashu, E.B., Nabilou, P., Junker, A.E., Galsgaard, E.D., Bendtsen, F., and Laupsa-Borge, J. (2024). Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease. BMC Gastroenterol., 24.","DOI":"10.1186\/s12876-024-03129-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1038\/s41598-026-36704-x","article-title":"NMR metabolomic signatures of healthy lifestyle and incident MASLD","volume":"16","author":"Tang","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1038\/s41598-022-10481-9","article-title":"Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool","volume":"12","author":"Babu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Grau, M., Casanova, P., Moreno-Morcillo, L., Morales, J.M., Marrachelli, V.G., and Monle\u00f3n, D. (2025). Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031288"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2400007","DOI":"10.1002\/ansa.202400007","article-title":"Challenges and recent advances in quantitative mass spectrometry-based metabolomics","volume":"26;5","author":"Ghafari","year":"2024","journal-title":"Anal. Sci. Adv."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"MSI Board Members, Sansone, S.A., Fan, T., Goodacre, R., Griffin, J.L., Hardy, N.W., Kaddurah-Daouk, R., Kristal, B.S., Lindon, J., and Mendes, P. (2007). The metabolomics standards initiative. Nat. Biotechnol., 25, 846\u2013848.","DOI":"10.1038\/nbt0807-846b"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","article-title":"Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI)","volume":"3","author":"Sumner","year":"2007","journal-title":"Metabolomics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/gutjnl-2024-332105","article-title":"Spatial single-cell omics: New insights into liver diseases","volume":"75","author":"Suo","year":"2026","journal-title":"Gut"},{"key":"ref_34","first-page":"111737","article-title":"Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Transforming diagnosis and therapeutic approaches","volume":"32","year":"2026","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gutjnl-2023-331740","article-title":"Artificial intelligence applied to omics data in liver disease: Towards a personalised approach for diagnosis, prognosis and treatment","volume":"74","author":"Ghosh","year":"2025","journal-title":"Gut"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: From mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sethi, P., Mishra, A.K., Ghosh, S., Singh, K.K., Sharma, S., Stojchevski, R., Avtanski, D., and Sinha, J.K. (2025). Lipid Metabolism-Signaling Crosstalk in Metabolic Disease and Aging: Mechanisms and Therapeutic Targets. Nutrients, 17.","DOI":"10.3390\/nu17233699"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.3390\/nu7115475","article-title":"The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis","volume":"7","author":"Saponaro","year":"2015","journal-title":"Nutrients"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.tem.2016.06.005","article-title":"The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis","volume":"27","author":"Herman","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00018-022-04401-3","article-title":"Contribution of specific ceramides to obesity-associated metabolic diseases","volume":"79","author":"Hammerschmidt","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2502978122","DOI":"10.1073\/pnas.2502978122","article-title":"Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis","volume":"122","author":"Sakuma","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Maccali","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ma, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., and Gao, Y. (2025). Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: An integrative perspective from molecular pathways to clinical challenges. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1639064"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1017\/S0954422424000179","article-title":"Ceramides as the molecular link between impaired lipid metabolism, saturated fatty acid intake and insulin resistance: Are all saturated fatty acids to be blamed for ceramide-mediated lipotoxicity?","volume":"38","author":"Sergi","year":"2025","journal-title":"Nutr. Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Waingerten-Kedem, L., Aviram, S., Blau, A., Hayek, T., and Bengal, E. (2024). P38\u03b1 MAPK Coordinates Mitochondrial Adaptation to Caloric Surplus in Skeletal Muscle. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147789"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mohiuddin, M.S., Neha, N.T., Mahir, J.U.K., Shakib, F.A.F., Alam, A., Wahiduzzaman, M., Barua, R., Shimu, S.J., Rahman, M., and Hossain, R. (2025). Metabolic dysfunction associated fatty liver disease and type 2 diabetes: Pathophysiological links, epidemiological trends, and clinical implications. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1669478"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sinha, R.A. (2023). Autophagy: A Cellular Guardian against Hepatic Lipotoxicity. Genes, 14.","DOI":"10.3390\/genes14030553"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri","year":"2009","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e198334","DOI":"10.1172\/JCI198334","article-title":"The pathogenesis of hepatic steatosis in MASLD: A lipid droplet perspective","volume":"135","author":"Krahmer","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e186420","DOI":"10.1172\/JCI186420","article-title":"MASH: The nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00018-025-05847-x","article-title":"Linc01271 promotes lipid synthesis and MASLD\/MASH progression via miR-149-3p\/RAB35 axis","volume":"82","author":"Yin","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Xue, L., Wang, X., and Mao, J. (2026). Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease. Front. Cell Dev. Biol., 14.","DOI":"10.3389\/fcell.2026.1808135"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"20261407","DOI":"10.1515\/med-2026-1407","article-title":"Mitochondrial medicine in obesity: A scoping review","volume":"21","author":"Lonardo","year":"2026","journal-title":"Open Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e18128","DOI":"10.1002\/advs.202518128","article-title":"F13A1-Mediated Macrophage Activation Promotes MASH Progression via the PKM2\/HIF1A Pathway","volume":"13","author":"Lu","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ji, F., Zhang, L., Ning, L., Zhang, M., and Zhang, J. (2026). Crosstalkof mitochondrial dysfunction macrophage polarization in sepis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1692597"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s43856-024-00465-3","article-title":"Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human","volume":"4","author":"Tsouka","year":"2024","journal-title":"Commun. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Radosavljevic, T., Brankovic, M., Samardzic, J., Djureti\u0107, J., Vukicevic, D., Vucevic, D., and Jakovljevic, V. (2024). Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches. Antioxidants, 13.","DOI":"10.3390\/antiox13080906"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3892\/ijmm_00000487","article-title":"Oxidative stress parameters in paediatric non-alcoholic fatty liver disease","volume":"26","author":"Nobili","year":"2010","journal-title":"Int. J. Mol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/hepr.12656","article-title":"The independent predictors of non-alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment","volume":"46","author":"Ballestri","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41422-025-01203-7","article-title":"Mitophagy in the pathogenesis and management of disease","volume":"36","author":"Wang","year":"2026","journal-title":"Cell Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chen, J., Jian, L., Guo, Y., Tang, C., Huang, Z., and Gao, J. (2024). Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis. Antioxidants, 13.","DOI":"10.3390\/antiox13060729"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1101\/gad.262758.115","article-title":"The three \u2018P\u2019s of mitophagy: PARKIN, PINK1, and post-translational modifications","volume":"29","author":"Durcan","year":"2015","journal-title":"Genes Dev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.12688\/f1000research.10397.1","article-title":"Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases","volume":"6","author":"Boyapati","year":"2017","journal-title":"F1000 Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s12276-023-00965-7","article-title":"Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e70213","DOI":"10.1002\/iid3.70213","article-title":"Molecular Mechanism of NLRP3 Inflammasome in Inflammatory Diseases and Tumors","volume":"13","author":"Gong","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s44466-025-00014-0","article-title":"NF-\u03baB: Master regulator of cellular responses in health and disease","volume":"1","author":"Hoffmann","year":"2025","journal-title":"Immun. Inflamm."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wu, Q., Yang, Y., Lin, S., Geller, D.A., and Yan, Y. (2025). The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1569915"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101414","DOI":"10.1016\/j.jhepr.2025.101414","article-title":"Inflammation in MASLD progression and cancer","volume":"7","author":"Kim","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_72","first-page":"106166","article-title":"Myeloperoxidase, extracellular DNA and neutrophil extracellular trap formation in the animal models of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Pastorek","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tem.2025.09.004","article-title":"Mechanisms and therapeutic insights into MASH-associated fibrosis","volume":"37","author":"Zhu","year":"2026","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2009.03.019","article-title":"Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis","volume":"51","author":"Argo","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.20517\/mtod.2024.42","article-title":"Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease","volume":"4","author":"Lonardo","year":"2024","journal-title":"Metab. Target Organ Damage"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M.E., Gasbarrini, A., and Zocco, M.A. (2025). Present and Future Perspectives in the Treatment of Liver Fibrosis. Pharmaceuticals, 18.","DOI":"10.3390\/ph18091321"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"E275\u2013281","DOI":"10.1152\/ajpendo.00644.2005","article-title":"Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells","volume":"291","author":"Wei","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1742-4658.2010.07972.x","article-title":"Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid-induced lipotoxicity in liver cells","volume":"278","author":"Mantzaris","year":"2011","journal-title":"FEBS J."},{"key":"ref_79","first-page":"1413","article-title":"Distinct Types of Cell Death and Implications in Liver Diseases: An Overview of Mechanisms and Application","volume":"11","author":"Wang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cmet.2020.10.026","article-title":"The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells","volume":"33","author":"Trivedi","year":"2021","journal-title":"Cell Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bbalip.2019.02.004","article-title":"Hepatic stellate cell activation: A source for bioactive lipids","volume":"1864","author":"Shmarakov","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Hou, W., and Syn, W.K. (2018). Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis. Front. Cell Dev. Biol., 6.","DOI":"10.3389\/fcell.2018.00150"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-022-05409-0","article-title":"Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis","volume":"13","author":"Yin","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/hep.27376","article-title":"Liver sinusoidal endothelial cells in hepatic fibrosis","volume":"61","author":"DeLeve","year":"2015","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ruan, B., Duan, J.L., Xu, H., Tao, K.S., Han, H., Dou, G.R., and Wang, L. (2021). Capillarized Liver Sinoidal Endothelial Cells Undergo Partial Endothelial-Mesenchymal Transition to Actively Deposit Sinusoidal ECM in Liver Fibrosis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.671081"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1369\/0022155415627681","article-title":"TGF-\u03b2\/SMAD Pathway and Its Regulation in Hepatic Fibrosis","volume":"64","author":"Xu","year":"2016","journal-title":"J. Histochem. Cytochem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.3892\/mmr.2017.7641","article-title":"PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review)","volume":"16","author":"Ying","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Foglia, B., Cannito, S., Bocca, C., Parola, M., and Novo, E. (2019). ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112700"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/CM9.0000000000003629","article-title":"MASLD development: From molecular pathogenesis toward therapeutic strategies","volume":"138","author":"Yang","year":"2025","journal-title":"Chin. Med. J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4093\/dmj.2025.0195","article-title":"Metabolic Sparks in the Liver: Metabolic and Epigenetic Reprogramming in Hepatic Stellate Cells Activation and Its Implications for Human Metabolic Diseases","volume":"49","author":"Roh","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5009\/gnl240407","article-title":"Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"19","author":"Pei","year":"2025","journal-title":"Gut. Liver"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1038\/s41467-024-49224-x","article-title":"PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein","volume":"15","author":"Johnson","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e144079","DOI":"10.1172\/jci.insight.144079","article-title":"Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans","volume":"5","author":"Adiels","year":"2020","journal-title":"JCI Insight"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis","volume":"74","author":"Teo","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1038\/s41467-023-38932-5","article-title":"The structure of phosphatidylinositol remodeling MBOAT7 reveals its catalytic mechanism and enables inhibitor identification","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease","volume":"378","author":"Cheng","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","article-title":"Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis","volume":"83","author":"Sanyal","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.20517\/mtod.2025.193","article-title":"Biological determinants and outcomes of sex discrepancies in MASLD","volume":"6","author":"Lonardo","year":"2026","journal-title":"Metab. Target Organ. Damage"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-P\u00e9rez, L., Santana-Farr\u00e9, R., de Mirecki-Garrido, M., Garc\u00eda, I., Guerra, B., Mateo-D\u00edaz, C., Iglesias-Gato, D., D\u00edaz-Chico, J.C., Flores-Morales, A., and D\u00edaz, M. (2014). Lipid profiling and transcriptomic analysis reveals a functional interplay between estradiol and growth hormone in liver. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096305"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Fotakis, C., Kalafati, I.P., Amanatidou, A.I., Andreou, V., Matzapetakis, M., Kafyra, M., Varlamis, I., Zervou, M., and Dedoussis, G.V. (2023). Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1230457"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacl.2025.08.010","article-title":"Greater alterations in atherogenic lipids and inflammatory markers in women during type 2 diabetes development and risk of coronary heart disease\u2013Findings from two population-based studies","volume":"19","author":"Yoshida","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_108","first-page":"1372","article-title":"Metabolic signatures of insulin resistance in 7098 young adults","volume":"61","author":"Soininen","year":"2012","journal-title":"Diabetes"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"H\u00fcttl, M., Markova, I., Zapletalova, I., and Malinska, H. (2026). Sex-specific aspects in the development of tissue metabolic damage in a non-obese prediabetic model. Front. Endocrinol., 17.","DOI":"10.3389\/fendo.2026.1786893"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.20517\/mtod.2025.131","article-title":"Sex and gender differences in MASLD: Pathophysiological mechanisms, clinical implications, and future directions","volume":"5","author":"Jamalinia","year":"2025","journal-title":"Metab. Target Organ Damage"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e0523","DOI":"10.1097\/HC9.0000000000000523","article-title":"Sex-and age-associated factors drive the pathophysiology of MASLD","volume":"8","author":"Yadav","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e180943","DOI":"10.1172\/jci.insight.180943","article-title":"Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and obese MASLD","volume":"10","author":"Haag","year":"2025","journal-title":"JCI Insight"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.maturitas.2021.10.004","article-title":"Metabolic profiling of charged metabolites in association with menopausal status in Japanese community-dwelling midlife women: Tsuruoka Metabolomic Cohort Study","volume":"155","author":"Watanabe","year":"2022","journal-title":"Maturitas"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e186421","DOI":"10.1172\/JCI186421","article-title":"Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics","volume":"135","author":"Colella","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3748\/wjg.v29.i19.2905","article-title":"Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties","volume":"29","author":"Marrone","year":"2023","journal-title":"World. J. Gastroenterol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4254\/wjh.v13.i12.1919","article-title":"Potential role of noninvasive biomarkers during liver fibrosis","volume":"13","author":"Kaur","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_118","first-page":"4058","article-title":"Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study","volume":"18","author":"Liu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10020-024-00830-x","article-title":"The gut microbiota-bile acid axis in cholestatic liver disease","volume":"30","author":"Sun","year":"2024","journal-title":"Mol. Med."},{"key":"ref_120","unstructured":"Feingold, K.R., Adler, R.A., Ahmed, S.F., Anawalt, B., Blackman, M.R., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., and Dungan, K. (2026, July 01). Lipid and Lipoprotein Metabolism in Liver Disease, Endotext, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326742\/."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2013.10.030","article-title":"Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology","volume":"232","author":"Loria","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s43856-025-01149-2","article-title":"Metabolomics for searching non-invasive biomarkers of metabolic dysfunction-associated steatotic liver disease in youth with vertical HIV","volume":"5","author":"Chafino","year":"2025","journal-title":"Commun. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14728222.2026.2671694","article-title":"Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Weiskirchen","year":"2026","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sahu, P., and Satapathy, T. (Probiotics Antimicrob. Proteins, 2026). The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets, Probiotics Antimicrob. Proteins, epub ahead of printing.","DOI":"10.1007\/s12602-026-11050-6"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Qiu, Y., Laguna, J.C., Alegret, M., and Vil\u00e0, L. (2026). A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation. Nutrients, 18.","DOI":"10.3390\/nu18040679"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"M\u00fcnte, E., and Hartmann, P. (2025). The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases. Biomolecules, 15.","DOI":"10.3390\/biom15040469"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e100204","DOI":"10.1136\/egastro-2025-100204","article-title":"Gut dysbiosis is linked to severe steatosis and enhances its diagnostic performance in MASLD","volume":"3","author":"Leite","year":"2025","journal-title":"eGastroenterology"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Chu, H., Song, X., Liu, C., Ma, T., and Cui, W. (2026). Gut microbial bile salt hydrolase as a metabolic gatekeeper in digestive homeostasis and disease. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1870619"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5625\/lar.2018.34.4.140","article-title":"Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis","volume":"34","author":"Kim","year":"2018","journal-title":"Lab. Anim. Res."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Tattoli, I., Mathew, A.R., Verrienti, A., Pallotta, L., Severi, C., Andreola, F., Cavallucci, V., Giorgi, M., Massimi, M., and Bencini, L. (2024). The Interplay between Liver and Adipose Tissue in the Onset of Liver Diseases: Exploring the Role of Vitamin Deficiency. Cells, 13.","DOI":"10.3390\/cells13191631"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1001334","DOI":"10.37349\/emed.2025.1001334","article-title":"Liver and obesity: A narrative review","volume":"6","author":"Lonardo","year":"2025","journal-title":"Explor. Med."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Pezzino, S., Luca, T., Castorina, M., Puleo, S., Latteri, S., and Castorina, S. (2024). Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines. Life, 14.","DOI":"10.3390\/life14010093"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2018-317584","article-title":"Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease","volume":"68","author":"Caussy","year":"2019","journal-title":"Gut"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Piras, C., Noto, A., Ibba, L., Deidda, M., Fanos, V., Muntoni, S., Leoni, V.P., and Atzori, L. (2021). Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review. Metabolites, 11.","DOI":"10.3390\/metabo11100694"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"159135","DOI":"10.1016\/j.bbalip.2022.159135","article-title":"Identification cholesterol metabolites altered before the onset of nonalcoholic steatohepatitis by targeted metabolomics","volume":"1867","author":"Shoji","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Ji, M., Jo, Y., Choi, S.J., Kim, S.M., Kim, K.K., Oh, B.C., Ryu, D., Paik, M.J., and Lee, D.H. (2022). Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071669"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Ahmed, E.A., El-Derany, M.O., Anwar, A.M., Saied, E.M., and Magdeldin, S. (2022). Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010210"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"121626","DOI":"10.1016\/j.lfs.2023.121626","article-title":"A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease","volume":"322","author":"Ganesan","year":"2023","journal-title":"Life Sci."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Dorochow, E., Kraus, N., Chenaux-Repond, N., Pierre, S., Kolbinger, A., Geisslinger, G., Ortiz, C., Welsch, C., Trebicka, J., and Gurke, R. (2023). Differential Lipidomics, Metabolomics and Immunological Analysis of Alcoholic and Non-Alcoholic Steatohepatitis in Mice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210351"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/acs.jproteome.3c00009","article-title":"Integration of Metabolomics, Lipidomics, and Proteomics Reveals the Metabolic Characterization of Nonalcoholic Steatohepatitis","volume":"22","author":"Zhang","year":"2023","journal-title":"J. Proteome Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Ogiso, H., Miura, K., Nagai, R., Osaka, H., and Aizawa, K. (2024). Non-Targeted Metabolomics Reveal Apomorphine\u2019s Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis. Antioxidants, 13.","DOI":"10.3390\/antiox13111293"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2024.10.015","article-title":"A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease","volume":"82","author":"Huang","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1021\/acs.analchem.5c04917","article-title":"Deep Multimodal Fusion Framework Integrating SERS, Clinical Data, and Metabolomics for Noninvasive MASH Diagnosis","volume":"98","author":"Wu","year":"2026","journal-title":"Anal. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jhep.2024.05.021","article-title":"Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms","volume":"81","author":"Papatheodoridi","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Zou, H., Pan, W., and Sun, X. (2025). Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: External validation utilizing data from two cohorts. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1571487"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17474124.2025.2557243","article-title":"Non-invasive assessment of liver fibrosis in MASLD: The need of sex-adjusted scores","volume":"19","author":"Novielli","year":"2025","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"117918","DOI":"10.1016\/j.trac.2024.117918","article-title":"A Reproducibility Crisis for Clinical Metabolomics Studies","volume":"180","author":"Cochran","year":"2024","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11306-023-02080-0","article-title":"Establishing a framework for best practices for quality assurance and quality control in untargeted metabolomics","volume":"20","author":"Mosley","year":"2024","journal-title":"Metabolomics"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"M\u00e4rtens, A., Holle, J., Mollenhauer, B., Wegner, A., Kirwan, J., and Hiller, K. (2023). Instrumental Drift in Untargeted Metabolomics: Optimizing Data Quality with Intrastudy QC Samples. Metabolites, 13.","DOI":"10.3390\/metabo13050665"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e2500001122","DOI":"10.1073\/pnas.2500001122","article-title":"Manifold fitting reveals metabolomic heterogeneity and disease associations in UK Biobank populations","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s44355-026-00061-3","article-title":"Diversity in metabolic dysfunction-associated steatotic liver disease: A framework for precision medicine","volume":"3","author":"Ko","year":"2026","journal-title":"npj Gut Liver"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.jhepr.2024.101133","article-title":"Dietary pattern modifies the risk of MASLD through metabolomic signature","volume":"6","author":"Wu","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pathmechdis-042624-091820","article-title":"Zonation, Zonation, Zonation: The Real Estate of the Liver","volume":"21","author":"Yasaka","year":"2026","journal-title":"Annu. Rev. Pathol."},{"key":"ref_156","unstructured":"(2026, July 01). MetaboLights. Available online: https:\/\/www.ebi.ac.uk\/metabolights\/."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/8\/529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:11:47Z","timestamp":1785147107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/8\/529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":156,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["metabo16080529"],"URL":"https:\/\/doi.org\/10.3390\/metabo16080529","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}